
Medically Reviewed By
Dr. Aditya Singh, MBBS, MD (Pharmacology)
Reg No: MCI-654321 • Verified Medical Reviewer
Truqap
(capivasertib)
Uses, side effects, dosage information & price range
About this medicine
Truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen. In pre- or perimenopausal women, Truqap plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist. For men, administration of LHRH agonist according to current clinical practice standards should be considered.
Common Substitutes & Alternatives
These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.
Key Information
Salt / Composition
capivasertib
Category
Antineoplastic agents
Manufacturer
AstraZeneca AB
Medical Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before taking any medication. Prices are indicative and may vary. Do not start, stop, or change the dosage of any medicine without your doctor's approval.
Disclaimer:Content on this page is for informational purposes only. Do not consume prescription medication without a registered practitioner's direct oversight.